乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02157 乐普生物

未开盘 07-15 16:08:35

4.890

+0.230

+4.94%

最高5.030	最低4.640	成交量1,841万
今开4.660	昨收4.660	日振幅8.37%
总市值88.22亿	流通市值88.22亿	总股本18.04亿
成交额9,006万	换手率1.02%	流通股本18.04亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02157","market":"HK","secType":"STK","nameCN":"乐普生物","latestPrice":4.89,"timestamp":1784102915003,"preClose":4.66,"halted":0,"volume":18408000,"delay":0,"changeRate":0.049356223175965566,"floatShares":1804000000,"shares":1804000000,"eps":0.148918,"marketStatus":"未开盘","change":0.23,"latestTime":"07-15 16:08:35","open":4.66,"high":5.03,"low":4.64,"amount":90062890,"amplitude":0.083691,"askPrice":4.9,"askSize":51000,"bidPrice":4.89,"bidSize":12000,"shortable":3,"etf":0,"ttmEps":0.165717,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784165400000},"marketStatusCode":0,"adr":0,"listingDate":1645545600000,"exchange":"SEHK","adjPreClose":4.66,"openAndCloseTimeList":[[1784079000000,1784088000000],[1784091600000,1784102400000]],"volumeRatio":1.797972,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02157","defaultTab":"news","newsList":[{"id":"1193879471","title":"乐普生物（02157.HK）公告监事变动 任方源接替赵力萱","url":"https://stock-news.laohu8.com/highlight/detail?id=1193879471","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193879471?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:56","pubTimestamp":1784105775,"startTime":"0","endTime":"0","summary":"2026年7月15日，乐普生物科技股份有限公司发布公告称，监事会于同日收到职工代表监事赵力萱女士的书面辞任函。赵女士因寻求其他事业发展，辞去职工代表监事职务，自2026年7月15日起生效。赵女士确认其在任期内与董事会及监事会并无意见分歧，亦无其他需提呈股东注意的事项。同日，乐普生物职工代表大会选举任方源女士为新任职工代表监事，任期自2026年7月15日起至本届监事会任期届满之日止。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455191","title":"乐普生物(02157.HK)：任方源获选举为职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455191","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651455191?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:53","pubTimestamp":1784105605,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455169","title":"乐普生物(02157)：任方源获选举为职工代表监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455169","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651455169?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:53","pubTimestamp":1784105605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物(02157)发布公告，于2026年7月15日，本公司监事会(监事会)收到本公司职工代表监事赵力萱女士(赵女士)的书面辞任函，赵女士因寻求其他事业发展辞任本公司职工代表监事。其辞任自2026年7月15日起生效。任方源女士(任女士)于本公司职工代表大会(职工代表大会)获选举为本公司职工代表监事，任期自2026年7月15日起至本届监事会任期届满之日止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651291435","title":"创新药概念全线扬升 科伦博泰生物(06990)涨逾11% 机构指创新药企迎业绩兑现窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2651291435","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651291435?lang=zh_cn&edition=full","pubTime":"2026-07-15 11:07","pubTimestamp":1784084836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念盘中全线扬升，截至发稿，欧康维视生物-B 涨13.35%，科伦博泰生物涨11.20%，康方生物涨8.82%，信达生物涨8.72%，三生制药涨8.11%，康诺亚-B涨7.62%，药明合联涨7.52%，荣昌生物涨7.09%，乐普生物涨6.87%，亚盛医药涨6.26%。该机构持续看好国内创新药出海β向上可持续性，提示投资者关注2027年起众多前期已达成BD的分子将在海外开启商业化新周期所带来的投资机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985914","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","LU0348767384.USD","LU2097828557.USD","BK1593","LU2097828805.USD","06978","LU1961090484.USD","LU2476274308.USD","LU0455707207.USD","LU0540923850.HKD","LU2097828631.EUR","BK1141","LU0348825331.USD","LU0348827113.USD","LU2097828474.EUR","IBBQ","06855","LU0417516902.SGD","06990","IE00BPRC5H50.USD","LU0417516738.SGD","LU0634319403.HKD","02157","BK1161","LU2778985437.USD","BK1574","IE00B543WZ88.USD","LU2328871848.SGD","01477","159992","BK1583","LU2097828714.EUR","09995","01530","KURE","LU0348784397.USD","02268","BK1191","LU0417516571.SGD","LU2488822045.USD","LU1720050803.USD","01801","MEDX","BK1587","BK1589","SG9999014674.SGD","LU2399975544.HKD","LU0561508036.HKD","LU0502904849.HKD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651433251","title":"港股异动 | 乐普生物(02157)再涨超7% MRG007有望成为潜在同类最佳(BIC)药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2651433251","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651433251?lang=zh_cn&edition=full","pubTime":"2026-07-15 10:22","pubTimestamp":1784082177,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物再涨超7%，月内累计涨幅接近30%。消息面上，乐普生物旗下MRG007临床申请已于今年5月正式获得国家药品监督管理局药品审评中心受理。MRG007凭借差异化技术优势，有望成为潜在同类最佳药物，进一步夯实公司在消化道肿瘤ADC领域的领先地位，并为后续全球多中心临床开发及潜在更多BD合作奠定坚实基础。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","KCAI","BK1161","VXUS","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192383407","title":"乐普生物2026年6月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1192383407","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192383407?lang=zh_cn&edition=full","pubTime":"2026-07-06 18:32","pubTimestamp":1783333940,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司于2026年7月6日披露2026年6月的证券变动月报表。报告显示，截至2026年6月30日，公司法定/注册股本总额为人民币18.04亿元，与上月底持平，期间并未进行新增发行、购回、注销或库藏股操作。在期权与激励计划、可换股票据以及其他可能导致股本变动的安排方面，月报披露并无相关事项。月报由乐普生物联席公司秘书李昀軼女士签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647082347","title":"港股异动 | 乐普生物(02157)午前涨超13% 机构指MRG006A有望推动肝癌精准治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2647082347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647082347?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:18","pubTimestamp":1782703131,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物午前涨超13%，截至发稿，涨12.57%，报4.03港元，成交额3631.49万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。国联民生证券此前发布研报称，MRG006A是国内首个申报临床、全球首个进入临床阶段的GPC3靶向ADC，具备FIC潜质。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460171.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4585","VXUS","02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","IE00BZ08YR35.GBP","LU2476274308.USD","LU0880133367.SGD","LU1720050803.USD","LU0072913022.USD","02162","LU1960683339.HKD","LU0140636845.USD","06978","LU0326950275.SGD","LU0348735423.USD","LU0348825331.USD","02228","LU0348783233.USD","LU1951186391.HKD","LU0417516571.SGD","06855","01530","LU0315179316.USD","LU1961090484.USD","LU0067412154.USD","LU2476274720.SGD","LU1226287792.SGD","09969","IE00B543WZ88.USD","LU1226288253.USD","02637","LU1328277881.USD","09995","IE00B5MMRT66.SGD","02157","LU0348767384.USD","01093","BK1574","LU1226287529.USD","159992","IE00BZ08YS42.EUR","LU0540923850.HKD","BK1141","LU0634319403.HKD","LU0348784397.USD","BK1583","LU1969619763.USD","09926","LU1008478684.HKD","LU0417516902.SGD","LU0348766576.USD","LU0348827113.USD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642257725","title":"港股异动 | 乐普生物-B(02157)午后涨超6% MRG006A治疗晚期肝癌I期临床数据优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2642257725","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642257725?lang=zh_cn&edition=full","pubTime":"2026-06-12 14:55","pubTimestamp":1781247321,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，乐普生物-B午后涨超6%，截至发稿，涨4.74%，报3.98港元，成交额4149.5万港元。消息面上，乐普生物在2026 ASCO上披露的MRG006A针对标准治疗失败后的晚期肝癌患者的I期临床试验数据相当优异。MRG006A切入的是全球尚无获批ADC的肝癌领域，代表的是尚未被充分开发的新路径，又已经初步跨过临床验证门槛。值得注意的是，乐普生物此前宣布其自主研发的靶向 CDH17 的抗体偶联药物MRG007 的新药临床试验申请正式获得国家药品监督管理局药品审评中心受理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453620.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02157","BK4585","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116936297","title":"乐普生物-B更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1116936297","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116936297?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:56","pubTimestamp":1780307796,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司于2026年6月1日发布截至2026年5月31日止的股份变动月报表，显示公司本月股本保持不变。根据公告，乐普生物-B的法定注册股本依旧为人民币1,804,439,838元，股票面值每股人民币1元。同时，公司确认，截至2026年5月31日，已符合香港联交所规定的最低公众持股量要求。本次公告由联席公司秘书李昀轶女士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636853239","title":"乐普生物(02157)：范馨予获选举为监事会监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2636853239","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636853239?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:38","pubTimestamp":1779190711,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物(02157)发布公告，自2026年5月19日起，范馨予女士获选举为第二届监事会监事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443574.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117370152","title":"乐普生物-B4月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1117370152","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117370152?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:56","pubTimestamp":1778144162,"startTime":"0","endTime":"0","summary":"乐普生物科技股份有限公司于2026年5月7日公布了2026年4月的证券变动月报表。根据公告，截至2026年4月末，公司已发行普通股合计1,804,439,838股，与上月持平，注册股本总额为人民币1,804,439,838元，面值每股1元。公告显示，报告期内未发生新股发行、购回或注销事项，也无新增或已行使的股份期权及其他股权激励计划安排。公告同时披露，公司截至4月底满足香港联交所的公众持股量要求，该等股份在数量及权利方面保持一致。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633133962","title":"乐普生物-B：5月11日起简称改为“乐普生物”","url":"https://stock-news.laohu8.com/highlight/detail?id=2633133962","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633133962?lang=zh_cn&edition=full","pubTime":"2026-05-06 20:11","pubTimestamp":1778069460,"startTime":"0","endTime":"0","summary":"5月6日，乐普生物-B（02157）发布公告，宣布香港联合交易所已批准上市规则第18A.09至18A.11条不适用本公司。自2026年5月11日起，本公司的中英文简称将不再加上标记“B”，股份将以新英文股份简称“LEPUBIO”和中文股份简称“乐普生物”在联交所买卖，股份代号仍为“2157”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605063728876463.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630397311","title":"乐普生物-B(02157)拟委任范馨予为监事","url":"https://stock-news.laohu8.com/highlight/detail?id=2630397311","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630397311?lang=zh_cn&edition=full","pubTime":"2026-04-27 21:47","pubTimestamp":1777297629,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普生物-B(02157)发布公告，董事会建议委任范馨予女士(范女士)为监事。倘获股东于股东周年大会上批准，彼之任期将自相关决议案于股东周年大会上获通过之日起至第二届董事会任期届满之日止，惟于彼的任期届满后可膺选连任。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159998665","title":"乐普生物-B(02157)2025年收入同比增逾150%成功扭亏，ADC管线与国际化布局加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=1159998665","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159998665?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:29","pubTimestamp":1776860993,"startTime":"0","endTime":"0","summary":"截至2025年12月31日止年度，乐普生物-B实现收入约人民币9.35亿元，较2024年的3.68亿元同比增长154.19%，并录得年内利润人民币2.59亿元，相较上一年度亏损4.24亿元显著改善。销售成本约人民币8,960万元，研发开支约人民币4.01亿元，占主要投入比例，较2024年度的4.38亿元有所下降。毛利率由上年的约79.66%提升至超过90%，显示盈利能力增强。核心商业化产品包括普枸单抗注射液和EGFR靶向ADC美佑恒，销售端实现约人民币5.01亿元收入。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"乐普生物-B(02157)2025年收入同比增逾150%成功扭亏，ADC管线与国际化布局加速推进","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625164562","title":"滨会生物冲刺港股：年亏1.2亿 乐普生物与扬子江药业是股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2625164562","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625164562?lang=zh_cn&edition=full","pubTime":"2026-04-05 14:23","pubTimestamp":1775370219,"startTime":"0","endTime":"0","summary":"武汉滨会生物科技股份有限公司（简称：“滨会生物”）日前更新招股书，准备在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260405/6391099581624874437279093.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260405/6391099581624874437279093.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33196/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["BK4585","VXUS","BK4588","02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","HK0000165453.HKD","01530","LU2328871848.SGD","01477","BK1587","BK1574","BK1583","159992","BK1161","06978","02157","06955","02162","LU1969619763.USD","02637","06855","BK1191","BK1593","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157446883","title":"异动解读 | 乐普生物-B盘中大涨9.13%，创新药概念走强受BD与业绩催化及AACR年会预期推动","url":"https://stock-news.laohu8.com/highlight/detail?id=1157446883","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157446883?lang=zh_cn&edition=full","pubTime":"2026-03-27 13:57","pubTimestamp":1774591020,"startTime":"0","endTime":"0","summary":"乐普生物-B今日盘中大涨9.13%，引起了市场的广泛关注。消息面上，创新药概念板块整体走强。行业数据显示，今年以来创新药出海业务发展（BD）持续高景气，总交易金额已超过去年全年水平，为板块提供了强劲动力。同时，近期多家同行业药企披露了亮眼的年度业绩，增强了市场对整个创新药行业盈利兑现能力的信心。此外，即将召开的美国癌症研究协会（AACR）年会上，预计将有大量中国药企携创新药产品亮相并发布重要临床数据，这一前瞻性事件也提振了市场对包括乐普生物-B在内的创新药企业的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622882066","title":"强业绩提振，港股通创新药逆市续涨，520880收复20日线！乐普生物-B绩后狂飙14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622882066","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622882066?lang=zh_cn&edition=full","pubTime":"2026-03-26 11:03","pubTimestamp":1774494180,"startTime":"0","endTime":"0","summary":"3月26日，港股通医药再度逆市表现，100%创新药研发标的——港股通创新药ETF华宝、港股医疗核心资产——港股通医疗ETF华宝双双高开，一度携手涨超1%！520880量价齐升，盘中收复20日线，实时成交超2亿元。　　创新药多股领跑，乐普生物-B盘中飙升逾14%站上半年线，领涨所有港股通标的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-26/doc-inhshtfa2929921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK4588","520880","BK4585","BK1574","02157","VXUS","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139201214","title":"异动解读 | 乐普生物-B盘中大涨6.71%，业绩利好推动股价上扬","url":"https://stock-news.laohu8.com/highlight/detail?id=1139201214","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139201214?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:41","pubTimestamp":1774489266,"startTime":"0","endTime":"0","summary":"乐普生物-B今日盘中股价大幅上涨6.71%，引发市场关注。报告期内，公司实现收入9.35亿元人民币，同比大幅增长154.19%；公司拥有人应占利润达到2.61亿元，成功实现同比扭亏为盈。此外，于2025年10月获批上市的新产品美佑恒在报告期内已贡献初步收入，进一步丰富了公司的商业化产品组合，为未来增长奠定了坚实基础。公司全球首创的EGFR靶向ADC药物美佑恒已在中国获批上市，同时有更多候选药物进入关键临床阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lepubiopharma.com","stockEarnings":[{"period":"1week","weight":0.1615},{"period":"1month","weight":0.2506},{"period":"3month","weight":-0.2488},{"period":"6month","weight":-0.1173},{"period":"1year","weight":-0.0449},{"period":"ytd","weight":-0.0161}],"compareEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":-0.0065},{"period":"3month","weight":-0.0649},{"period":"6month","weight":-0.0806},{"period":"1year","weight":0.0037},{"period":"ytd","weight":-0.037}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"乐普生物科技股份有限公司是一家主要从事医药产品销售及新药研发的公司。该公司聚焦于肿瘤治疗领域，尤其是靶向治疗及免疫治疗。该公司致力于通过抗体药物偶联物（ADC）技术开发平台开发创新型ADC。该公司的临床阶段候选药物涵盖靶向疗法药物和一种免疫治疗药物，具体包括MRG003、MRG002、CMG901、MRG004A、CG0070、MRG006A、MRG007、CTM012等。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070458},{"month":2,"riseRate":0.5,"avgChangeRate":0.087235},{"month":3,"riseRate":0.4,"avgChangeRate":-0.009016},{"month":4,"riseRate":0.8,"avgChangeRate":0.177486},{"month":5,"riseRate":0.4,"avgChangeRate":-0.041488},{"month":6,"riseRate":0.4,"avgChangeRate":-0.053819},{"month":7,"riseRate":0.6,"avgChangeRate":0.105412},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002458},{"month":9,"riseRate":0.5,"avgChangeRate":0.085192},{"month":10,"riseRate":0.25,"avgChangeRate":-0.14162},{"month":11,"riseRate":0.25,"avgChangeRate":0.007333},{"month":12,"riseRate":0.25,"avgChangeRate":-0.05091}],"exchange":"SEHK","name":"乐普生物","nameEN":"LEPU BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供乐普生物(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"乐普生物,02157,乐普生物股票,乐普生物股票老虎,乐普生物股票老虎国际,乐普生物行情,乐普生物股票行情,乐普生物股价,乐普生物股市,乐普生物股票价格,乐普生物股票交易,乐普生物股票购买,乐普生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"乐普生物(02157)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供乐普生物(02157)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}